RPRX Royalty Pharma Plc

Royalty Pharma has acquired a pre-existing royalty interest in Nuvalent’s oncology drugs, neladalkib and zidesamtinib, for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for NSCLC, with neladalkib showing positive pivotal results and zidesamtinib currently under FDA review. Analysts project significant sales for both therapies by 2035, securing Royalty Pharma a low-single-digit royalty on worldwide net sales until approximately 2041-2042.

Royalty Pharma plc announced the acquisition of a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for ALK and ROS1 mutation-positive non-small cell lung cancer, respectively. The transaction covers a low-single digit royalty on worldwide net sales for both therapies, with an expected duration extending through approximately 2041 to 2042.

Advances in novel therapies are accelerating survival gains for pancreatic cancer patients. Oncolytics Biotech Inc. is preparing for a pivotal Phase 3 study of pelareorep, an immunotherapy, in first-line metastatic pancreatic cancer, while Immuneering Corporation and Tango Therapeutics, Inc. have reported promising clinical data for their respective treatments. Moderna and Royalty Pharma plc are also investing in and supporting oncology advancements.

Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. This transaction was conducted under a pre-arranged 10b5-1 trading plan. Despite Coyne's share sale, Royalty Pharma recently reported robust Q3 2025 financial results and raised its full-year guidance, leading to a positive adjustment in its price target by Goldman Sachs.

Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. These transactions were conducted under a pre-arranged 10b5-1 trading plan. This sale follows recent positive financial results for Royalty Pharma, including an 11% increase in third-quarter portfolio receipts and raised full-year guidance.

Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. These transactions were executed under a pre-arranged 10b5-1 trading plan. The sale occurred amidst Royalty Pharma reporting robust Q3 2025 financial results and raising its full-year guidance.